BR112022017557A2 - Método para tratar doenças pulmonares inflamatórias com o uso de células-tronco ou precursoras de linhagem mesenquimal - Google Patents

Método para tratar doenças pulmonares inflamatórias com o uso de células-tronco ou precursoras de linhagem mesenquimal

Info

Publication number
BR112022017557A2
BR112022017557A2 BR112022017557A BR112022017557A BR112022017557A2 BR 112022017557 A2 BR112022017557 A2 BR 112022017557A2 BR 112022017557 A BR112022017557 A BR 112022017557A BR 112022017557 A BR112022017557 A BR 112022017557A BR 112022017557 A2 BR112022017557 A2 BR 112022017557A2
Authority
BR
Brazil
Prior art keywords
stem cells
inflammatory lung
lung diseases
treat inflammatory
line precursor
Prior art date
Application number
BR112022017557A
Other languages
English (en)
Portuguese (pt)
Inventor
Itescu Silviu
Original Assignee
Mesoblast Int Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020900685A external-priority patent/AU2020900685A0/en
Application filed by Mesoblast Int Sarl filed Critical Mesoblast Int Sarl
Publication of BR112022017557A2 publication Critical patent/BR112022017557A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
BR112022017557A 2020-03-05 2021-03-04 Método para tratar doenças pulmonares inflamatórias com o uso de células-tronco ou precursoras de linhagem mesenquimal BR112022017557A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2020900685A AU2020900685A0 (en) 2020-03-05 Method for treating inflammatory lung diseases using mesenchymal lineage precursor or stem cells
PCT/EP2021/055483 WO2021176001A1 (en) 2020-03-05 2021-03-04 Method for treating inflammatory lung diseases using mesenchymal lineage precursor or stem cells

Publications (1)

Publication Number Publication Date
BR112022017557A2 true BR112022017557A2 (pt) 2022-12-27

Family

ID=74867509

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022017557A BR112022017557A2 (pt) 2020-03-05 2021-03-04 Método para tratar doenças pulmonares inflamatórias com o uso de células-tronco ou precursoras de linhagem mesenquimal

Country Status (9)

Country Link
US (1) US20230293589A1 (https=)
EP (1) EP4114418A1 (https=)
JP (1) JP2023517035A (https=)
KR (1) KR20220150919A (https=)
CN (1) CN115361958A (https=)
AU (1) AU2021232614A1 (https=)
BR (1) BR112022017557A2 (https=)
CA (1) CA3170255A1 (https=)
WO (1) WO2021176001A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120087868A1 (en) 2010-10-08 2012-04-12 Gabriele Todd Nanoparticle-loaded cells
SG11202004680UA (en) 2017-11-22 2020-06-29 Mesoblast Int Sarl Cellular compositions and methods of treatment i
EP4181935A1 (en) * 2020-07-20 2023-05-24 Brainstorm Cell Therapeutics Ltd. Methods and compositions for treating lung conditions

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US6251295B1 (en) 1998-01-08 2001-06-26 Nexell Therapeutics Inc. Method for recirculation washing of blood cells
EP3461884B1 (en) * 2004-03-22 2025-05-28 Mesoblast International Sàrl Mesenchymal stem cells and uses therefor
US20080095749A1 (en) * 2004-03-22 2008-04-24 Sudeepta Aggarwal Mesenchymal stem cells and uses therefor
US20120087868A1 (en) * 2010-10-08 2012-04-12 Gabriele Todd Nanoparticle-loaded cells
WO2015016761A2 (en) * 2013-08-01 2015-02-05 Isletone Ab Mscs in the treatment of inflammatory pulmonary diseases
CN105796598A (zh) * 2014-12-29 2016-07-27 西比曼生物科技（上海）有限公司 一种用于治疗慢性阻塞性肺疾病的脂肪间充质祖细胞复合物
US20200108099A1 (en) * 2017-02-15 2020-04-09 Rohto Pharmaceutical Co., Ltd. Therapeutic agent for pulmonary fibrosis, ptprr expression-promotor, and kit for treatment of pulmonary fibrosis
CL2017002357A1 (es) * 2017-09-16 2018-04-20 Cells For Cells S A Método de obtención de una composición que contiene una población específica de células mesenquimales de cordón umbilical y sus usos
CN111297899A (zh) * 2020-02-21 2020-06-19 云南雅盛医疗科技有限公司 一种脐带间充质干细胞在制备治疗新型冠状肺炎药物中的应用

Also Published As

Publication number Publication date
US20230293589A1 (en) 2023-09-21
AU2021232614A1 (en) 2022-09-29
WO2021176001A1 (en) 2021-09-10
JP2023517035A (ja) 2023-04-21
EP4114418A1 (en) 2023-01-11
CA3170255A1 (en) 2021-09-10
CN115361958A (zh) 2022-11-18
KR20220150919A (ko) 2022-11-11

Similar Documents

Publication Publication Date Title
BR112022020042A2 (pt) Método para tratar hiperinflamação com o uso de células-tronco ou precursoras de linhagem mesenquimal
BR112022017557A2 (pt) Método para tratar doenças pulmonares inflamatórias com o uso de células-tronco ou precursoras de linhagem mesenquimal
MX2024003145A (es) Tratamiento para el sindrome de supresion del 22q11.2 con cannabidiol.
BR112022018022A2 (pt) Método para tratar doença inflamatória intestinal ii
AR081450A1 (es) Tratamiento de sarcoidosis usando celulas madre de placenta
BRPI0810118A8 (pt) Método para tratar doença, método para efetuar profilaxia contra caa, uso de um agente, método para reduzir amilóide vascular em um paciente, e, kit para tratamento
BR112017027411A2 (pt) inibidores de nadph oxidase 4
MX2022003193A (es) Tratamiento de encefalopatia asociada al gen syngap1.
CO6331301A2 (es) Combinaciones y metodos para administracion subcutanea de inmunoglobulina y hialuronidasa
BR112022016448A2 (pt) Método para tratamento de doença do enxerto contra hospedeiro crônica
BR112022017560A2 (pt) Método para tratar doença inflamatória intestinal i
ZA202000680B (en) Obinutuzumab treatment of a dlbcl patient subgroup
BR112022007721A2 (pt) Método para o tratamento da demência
BR112023020669A2 (pt) Terapias de combinação para o tratamento de câncer
BR112016000658A2 (pt) pancreatina de alta atividade, processo para a preparação de pancreatina de aa tendo atividade lipásica específica de pelo menos aproximadamente 120 usp iu/mg e método de tratamento de um paciente sujeito a uma condição patológica associada com a insuficiência enzimática pandreática
BR112021020525A2 (pt) Agente terapêutico para câncer urológico que se caracteriza por ser administrado com inibidor de il-6 e inibidor de ccr2 em combinação
MX2021013901A (es) Composiciones y métodos para el tratamiento del cáncer.
BR112015019197A2 (pt) tratamento de doença de enxerto versus hospedeiro em pacientes transplantados
BR112014016950A2 (pt) métodos de promoção da cicatrização de úlceras diabéticas utilizando beta-hidróxi-beta-metilbutirato com arginina e glutamina
BR112023021840A2 (pt) Método para tratar síndrome da dificuldade respiratória aguda (ards) com o uso de percursor de linhagem mesenquimal ou células-tronco
BRPI0512503A (pt) composição que compreende ácido lático e lactoferrina
BR112022020392A2 (pt) Método para tratar um indivíduo que tem doença de huntington, inibidor do bromodomínio 9, e, uso de um inibidor do bromodomínio 9
CL2022002239A1 (es) Tafoxiparina para el tratamiento de la preeclampsia
BR112023026559A2 (pt) Formas cristalinas de trofinetida
AR114147A1 (es) Uso tópico y entrega de microorganismos oxidantes de amoníaco